Key result
Early intracoronary administration of nicorandil significantly increased the achievement of TIMI grade 3 flow to 96.67% compared to 86.67% with placebo in patients with acute myocardial infarction.
Why the study?
Does early intracoronary administration of nicorandil improve myocardial microcirculation and reduce infarct size in patients with acute anterior wall ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
RCT (n=120)
Single-blind
Random number table
No
Does early intracoronary administration of nicorandil improve myocardial microcirculation and reduce infarct size in patients with acute anterior wall ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Absolute Event Rate: 96.67% vs 86.67%
p-value: p=0.047
Early intracoronary administration of nicorandil during primary PCI significantly improves myocardial microcirculation and reduces infarct size in patients with acute anterior wall STEMI.
Supports adjunctive intracoronary nicorandil in anterior STEMI primary PCI; extends RCT evidence for microvascular protection.
INTRODUCTION: Prevention of the no-reflow phenomenon has a crucial role in primary percutaneous coronary intervention (P-PCI) procedures. AIM: To assess the effects of early intracoronary administration of nicorandil (NIC) during P-PCI on myocardial microcirculation in patients with acute myocardial infarction (AMI). MATERIAL AND METHODS: -MIBI SPECT) findings 10 days after surgery were compared between the two groups. RESULTS: = 0.014). CONCLUSIONS: Early coronary administration of NIC can significantly reduce the damage in the myocardial microcirculation caused by P-PCI and the myocardial infarct size in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2018) conducted an RCT in Acute anterior wall ST segment elevation myocardial infarction (AASTMI) (n=120). Nicorandil vs. Placebo (normal saline) was evaluated on Achievement of TIMI grade 3 flow (p=0.047). Early intracoronary administration of nicorandil significantly increased the achievement of TIMI grade 3 flow to 96.67% compared to 86.67% with placebo in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: